Which has better valuation & earnings, ELUT or CVRX?

Elutia has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.29M 2.83 $53.38M $0.86 0.95 CVRx $56.65M 1.11 -$53.31M -$1.98 N/A

Is ELUT or CVRX more profitable?

Elutia has a net margin of 312.09% compared to CVRx's net margin of -84.93%. Elutia's return on equity of 0.00% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 312.09% N/A -53.97% CVRx -84.93% -152.35% -50.93%

Does the media favor ELUT or CVRX?

In the previous week, CVRx had 21 more articles in the media than Elutia. MarketBeat recorded 22 mentions for CVRx and 1 mentions for Elutia. Elutia's average media sentiment score of 0.00 beat CVRx's score of -0.40 indicating that Elutia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Is RCEL or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Avita Medical's net margin of -56.96%. Company Net Margins Return on Equity Return on Assets Avita Medical -56.96% N/A -78.53% Elutia 312.09% N/A -53.97%

Does the media refer more to RCEL or ELUT?

In the previous week, Avita Medical had 9 more articles in the media than Elutia. MarketBeat recorded 10 mentions for Avita Medical and 1 mentions for Elutia. Avita Medical's average media sentiment score of 0.55 beat Elutia's score of 0.00 indicating that Avita Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avita Medical 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MBOT or ELUT?

In the previous week, Microbot Medical had 2 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Microbot Medical and 1 mentions for Elutia. Microbot Medical's average media sentiment score of 0.52 beat Elutia's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer KEQU or ELUT?

Elutia has a consensus price target of $6.00, suggesting a potential upside of 637.10%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Elutia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to KEQU or ELUT?

In the previous week, Kewaunee Scientific and Kewaunee Scientific both had 1 articles in the media. Kewaunee Scientific's average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kewaunee Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, HYPR or ELUT?

Elutia has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 8.27 -$35.57M -$0.38 N/A Elutia $12.29M 2.83 $53.38M $0.86 0.95

Is HYPR or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Hyperfine's net margin of -210.75%. Elutia's return on equity of 0.00% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -99.81% -64.95% Elutia 312.09% N/A -53.97%

Does the media prefer HYPR or ELUT?

In the previous week, Hyperfine had 8 more articles in the media than Elutia. MarketBeat recorded 9 mentions for Hyperfine and 1 mentions for Elutia. Hyperfine's average media sentiment score of 0.36 beat Elutia's score of 0.00 indicating that Hyperfine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Elutia (ELUT) Competitors

$0.81 -0.04 (-4.24%)

As of 04:00 PM Eastern

Compare

ELUT vs. CVRX, RCEL, MBOT, KEQU, and HYPR

Should you buy Elutia stock or one of its competitors? Elutia's main competitors and comparable companies include CVRx (CVRX), Avita Medical (RCEL), Microbot Medical (MBOT), Kewaunee Scientific (KEQU), and Hyperfine (HYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Elutia compare to CVRx?

Elutia (NASDAQ:ELUT) and CVRx (NASDAQ:CVRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Elutia has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	2.83	$53.38M	$0.86	0.95
CVRx	$56.65M	1.11	-$53.31M	-$1.98	N/A

In the previous week, CVRx had 21 more articles in the media than Elutia. MarketBeat recorded 22 mentions for CVRx and 1 mentions for Elutia. Elutia's average media sentiment score of 0.00 beat CVRx's score of -0.40 indicating that Elutia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CVRx	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

74.0% of Elutia shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 17.8% of Elutia shares are owned by company insiders. Comparatively, 16.6% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elutia currently has a consensus target price of $6.00, indicating a potential upside of 637.10%. CVRx has a consensus target price of $6.90, indicating a potential upside of 191.14%. Given Elutia's higher probable upside, equities analysts plainly believe Elutia is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CVRx	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Elutia has a net margin of 312.09% compared to CVRx's net margin of -84.93%. Elutia's return on equity of 0.00% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
CVRx	-84.93%	-152.35%	-50.93%

Elutia has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, CVRx has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Elutia beats CVRx on 9 of the 15 factors compared between the two stocks.

How does Elutia compare to Avita Medical?

Avita Medical (NASDAQ:RCEL) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Avita Medical had 9 more articles in the media than Elutia. MarketBeat recorded 10 mentions for Avita Medical and 1 mentions for Elutia. Avita Medical's average media sentiment score of 0.55 beat Elutia's score of 0.00 indicating that Avita Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avita Medical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avita Medical presently has a consensus price target of $8.25, suggesting a potential upside of 8.55%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 637.10%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by company insiders. Comparatively, 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avita Medical has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market. Comparatively, Elutia has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Avita Medical's net margin of -56.96%.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Elutia	312.09%	N/A	-53.97%

Elutia has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	3.27	-$48.59M	-$1.44	N/A
Elutia	$12.29M	2.83	$53.38M	$0.86	0.95

Summary

Avita Medical and Elutia tied by winning 7 of the 14 factors compared between the two stocks.

How does Elutia compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Microbot Medical had 2 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Microbot Medical and 1 mentions for Elutia. Microbot Medical's average media sentiment score of 0.52 beat Elutia's score of 0.00 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Microbot Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Elutia has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Elutia has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A
Elutia	$12.29M	2.83	$53.38M	$0.86	0.95

Elutia has a net margin of 312.09% compared to Microbot Medical's net margin of 0.00%. Elutia's return on equity of 0.00% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Elutia	312.09%	N/A	-53.97%

Microbot Medical presently has a consensus target price of $6.63, suggesting a potential upside of 242.38%. Elutia has a consensus target price of $6.00, suggesting a potential upside of 637.10%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 4.7% of Microbot Medical shares are held by company insiders. Comparatively, 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Elutia beats Microbot Medical on 8 of the 15 factors compared between the two stocks.

How does Elutia compare to Kewaunee Scientific?

Kewaunee Scientific (NASDAQ:KEQU) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Elutia has a consensus price target of $6.00, suggesting a potential upside of 637.10%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has lower revenue, but higher earnings than Kewaunee Scientific. Elutia is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282M	0.37	$9.62M	$3.22	11.31
Elutia	$12.29M	2.83	$53.38M	$0.86	0.95

Elutia has a net margin of 312.09% compared to Kewaunee Scientific's net margin of 3.41%. Kewaunee Scientific's return on equity of 14.10% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	3.41%	14.10%	5.55%
Elutia	312.09%	N/A	-53.97%

Kewaunee Scientific has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Elutia has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

32.7% of Kewaunee Scientific shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 14.1% of Kewaunee Scientific shares are owned by company insiders. Comparatively, 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kewaunee Scientific and Kewaunee Scientific both had 1 articles in the media. Kewaunee Scientific's average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kewaunee Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elutia beats Kewaunee Scientific on 8 of the 12 factors compared between the two stocks.

How does Elutia compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Elutia has a net margin of 312.09% compared to Hyperfine's net margin of -210.75%. Elutia's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-99.81%	-64.95%
Elutia	312.09%	N/A	-53.97%

Elutia has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.27	-$35.57M	-$0.38	N/A
Elutia	$12.29M	2.83	$53.38M	$0.86	0.95

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 17.8% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Hyperfine had 8 more articles in the media than Elutia. MarketBeat recorded 9 mentions for Hyperfine and 1 mentions for Elutia. Hyperfine's average media sentiment score of 0.36 beat Elutia's score of 0.00 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperfine currently has a consensus price target of $1.74, indicating a potential upside of 82.89%. Elutia has a consensus price target of $6.00, indicating a potential upside of 637.10%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hyperfine has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Elutia has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Elutia beats Hyperfine on 8 of the 15 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.37M	$5.79B	$7.06B	$12.95B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	N/A	24.71	269.75	24.74
Price / Sales	2.83	67.44	652.34	108.60
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	1.25	6.21	11.27	6.42
Net Income	$53.38M	$147.87M	$3.45B	$347.12M
7 Day Performance	-6.10%	3.40%	3.56%	2.48%
1 Month Performance	-15.47%	1.66%	-0.58%	-1.04%
1 Year Performance	-59.50%	6.26%	77.52%	23.22%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	2.7141 of 5 stars	$0.81 -4.2%	$6.00 +637.1%	-57.7%	$36.37M	$12.29M	N/A	180	Upcoming Earnings
CVRX CVRx	2.2927 of 5 stars	$5.58 +1.6%	$11.50 +106.1%	-67.0%	$148.09M	$56.65M	N/A	160	News Coverage Earnings Report Analyst Downgrade
RCEL Avita Medical	2.5889 of 5 stars	$4.47 -3.5%	$7.25 +62.2%	+82.8%	$137.59M	$71.61M	N/A	130	Earnings Report Analyst Upgrade
MBOT Microbot Medical	2.1907 of 5 stars	$1.85 +1.6%	$6.63 +258.1%	-38.8%	$124.26M	N/A	N/A	20	Upcoming Earnings
KEQU Kewaunee Scientific	0.8444 of 5 stars	$36.40 +0.3%	N/A	-29.5%	$104.47M	$282M	11.30	1,231	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors

ELUT vs. CVRX, RCEL, MBOT, KEQU, and HYPR

How does Elutia compare to CVRx?

Summary

How does Elutia compare to Avita Medical?

Summary

How does Elutia compare to Microbot Medical?

Summary

How does Elutia compare to Kewaunee Scientific?

Summary

How does Elutia compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elutia (ELUT) Competitors

ELUT vs. CVRX, RCEL, MBOT, KEQU, and HYPR

How does Elutia compare to CVRx?

Which has better valuation & earnings, ELUT or CVRX?

Does the media favor ELUT or CVRX?

Do institutionals & insiders hold more shares of ELUT or CVRX?

Do analysts rate ELUT or CVRX?

Is ELUT or CVRX more profitable?

Which has more risk and volatility, ELUT or CVRX?

Summary

How does Elutia compare to Avita Medical?

Does the media refer more to RCEL or ELUT?

Do analysts recommend RCEL or ELUT?

Do institutionals and insiders have more ownership in RCEL or ELUT?

Which has more risk and volatility, RCEL or ELUT?

Is RCEL or ELUT more profitable?

Which has stronger valuation and earnings, RCEL or ELUT?

Summary

How does Elutia compare to Microbot Medical?

Does the media prefer MBOT or ELUT?

Which has more volatility & risk, MBOT or ELUT?

Which has higher earnings and valuation, MBOT or ELUT?

Is MBOT or ELUT more profitable?

Do analysts rate MBOT or ELUT?

Do institutionals & insiders hold more shares of MBOT or ELUT?

Summary

How does Elutia compare to Kewaunee Scientific?

Do analysts prefer KEQU or ELUT?

Which has higher valuation & earnings, KEQU or ELUT?

Is KEQU or ELUT more profitable?

Which has more risk & volatility, KEQU or ELUT?

Do institutionals and insiders have more ownership in KEQU or ELUT?

Does the media refer more to KEQU or ELUT?

Summary

How does Elutia compare to Hyperfine?

Is HYPR or ELUT more profitable?

Which has stronger valuation & earnings, HYPR or ELUT?

Do institutionals & insiders believe in HYPR or ELUT?

Does the media prefer HYPR or ELUT?

Do analysts prefer HYPR or ELUT?

Which has more risk and volatility, HYPR or ELUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools